Drug · DIN 02242815
SIMULECT
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 23, 2000; first marketed October 23, 2000.
- Drug Identification Number (DIN)
- 02242815
- Company (DIN owner)
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Schedule
- Prescription; Schedule d
- Dosage form
- Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Basiliximab L04AC02
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| BASILIXIMAB | 20 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- September 1, 2000: NOC 989New Drug Submission (NDS)